Publications by authors named "David Buttar"

Claim this Profile
T
The Global Characterisation of a Drug-Dendrimer Conjugate - PEGylated poly-lysine Dendrimer.
Nadim Akhtar, Marianne B Ashford, Louisa Beer, Alex Bowes, Tony Bristow, David Buttar

J Pharm Sci· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology.
Frederick W Goldberg, Jason G Kettle, Gillian M Lamont, David Buttar, Attilla K T Ting

J Med Chem· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of a Nitromethane-Carbonylation Strategy during Route Design of an Atropisomeric KRAS Inhibitor.
James J Douglas, Matthew R Tatton, Daniël de Bruin, David Buttar, Calum Cook

J Org Chem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine learning meets mechanistic modelling for accurate prediction of experimental activation energies.
Kjell Jorner, Tore Brinck, Per-Ola Norrby, David Buttar

Chem Sci· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.
James S Scott, Andrew Bailey, David Buttar, Rodrigo J Carbajo, Jon Curwen

J Med Chem· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solubility prediction from first principles: a density of states approach.
Simon Boothroyd, Andy Kerridge, Anders Broo, David Buttar, Jamshed Anwar

Phys Chem Chem Phys· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Hazel M Weir, Robert H Bradbury, Mandy Lawson, Alfred A Rabow, David Buttar

Cancer Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.
Chris De Savi, Robert H Bradbury, Alfred A Rabow, Richard A Norman, Camila de Almeida, David Buttar

J Med Chem· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
Matt Addie, Peter Ballard, David Buttar, Claire Crafter, Gordon Currie

J Med Chem· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.
M Raymond V Finlay, David Buttar, Susan E Critchlow, Allan P Dishington, Shaun M Fillery

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated QSAR with a Hierarchy of Global and Local Models.
David J Wood, David Buttar, John G Cumming, Andrew M Davis, Ulf Norinder

Mol Inform· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
David Buttar, Nicola Colclough, Stefan Gerhardt, Philip A MacFaul, Scott D Phillips

Bioorg Med Chem· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.
Richard W A Luke, Peter Ballard, David Buttar, Leonie Campbell, Jon Curwen

Bioorg Med Chem Lett· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
David Buttar, Mike Edge, Steve C Emery, Martina Fitzek, Cheryl Forder

Bioorg Med Chem Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scaffold hopping using clique detection applied to reduced graphs.
Edward J Barker, David Buttar, David A Cosgrove, Eleanor J Gardiner, Paula Kitts

J Chem Inf Model· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis